Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis

Kelekçi, Sefa; Kelekci, Kiymet Handan; Yılmaz, Bülent

doi:10.1016/j.contraception.2012.04.001

Cited by 48 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LNG-IUS is used as an effective treatment reducing adenomyosisassociated menorrhagia with a significant increase in Hb, hematocrit, and serum ferritin [11,20,21] In our study, there was a significant reduction in bleeding volume/ cycle 3 months, 6 months, 1 year, and continue to decrease 2 years after insertion of Mirena. Dysmenorrhea also showed significant improvement 3, 6 months, and 1 year after Mirena insertion.…”

Section: Discussionsupporting

confidence: 52%

Levonorgestrel-Releasing Intrauterine System in Adenomyosis; Predictors for Response and Clinical Outcome

Alizzi

Showman

Fawzi

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives:The aim is to detect clinical and ultrasonographic characters that predict the response of adenomyosis to levonorgestrel-releasing intrauterine system (LNG-IUS) and to evaluate the clinical efficacy and the time needed to show a response. Methods:A prospective single-arm study conducted in the Obstetrics and Gynaecology Department Al-Yarmouk Teaching Hospital in Baghdad/Iraq from August 2015 to March 2018. Women with symptomatic adenomyosis with age 39 years and above and who completed their families had been enrolled in this study. LNG-IUS was used as a treatment; the outcome measure was to evaluate its effect in improving the symptoms and the time needed to show a clinical response. Multivariate analysis was used to assess the contribution of the clinical and ultrasonographic parameters to the prediction of the response to LNG-IUS. Results:Over the mean duration of follow-up period of the study (22.7±9.9 months), there was a significant improvement in menstrual blood loss, dysmenorrhea, and hemoglobin (Hb) with significant decrease in uterine volume (p˂0.001). The time to show response was as early as 3 months and the first 6 months is the best time to predict failure. Initial menstrual blood loss and Hb were good predictors to show response while uterine volume an excellent one (positive predictive value 80% and negative predictive value 97.2%). Conclusion:Levonorgestrel-releasing intrauterine device is an effective treatment of symptomatic adenomyosis in term of time to response and duration of response. The presenting Hb, menstrual blood loss, and uterine volume are useful predictors of response.

show abstract

Section: Discussionsupporting

confidence: 52%

Levonorgestrel-Releasing Intrauterine System in Adenomyosis; Predictors for Response and Clinical Outcome

Alizzi

Showman

Fawzi

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…[34] A study comparing the effects of the LNG-IUS and the copper T380A intrauterine device on menstruation and dysmenorrhea showed a significant improvement in duration of the menstrual bleeding, dysmenorrhea, and hemoglobin in the LNG-IUS treatment group than the other groups. [35] Another study conducted by Sheng, et al . [36] reported that LNG-IUS use relieved dysmenorrhea associated with adenomyosis in a follow-up period of 3 years.…”

Section: Introductionmentioning

confidence: 99%

Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding

et al. 2013

View full text Add to dashboard Cite

A review of literature was conducted to report on the effectiveness of levonorgestrel intrauterine system (LNG-IUS) in women with heavy menstrual bleeding (HMB). The relevant data were obtained by computerized searches of PubMed up to December 2012 and other references available with the authors. Information was obtained from references listed. Studies and case reports were excluded if they did not specifically provide information about LNG-IUS usage in women with HMB. After perusal, each relevant publication was summarized and appraised in terms of whether it contained information relevant to the stated objective. Available data shows that LNG-IUS therapy is effective and safe, providing significant reduction of menstrual bleeding in patients with HMB. LNG-IUS is a good strategy to reduce the number of hysterectomies in women with HMB.

show abstract

“…19 Hormonal medications may be associated with side effects of varying tolerability, and as the underlying mechanism is lesion suppression rather than destruction, symptom relief is usually restricted to the duration of treatment. [20][21][22] A particular difficulty of intrauterine devices is involuntary expulsion of the device, which is exacerbated by menorrhagia and an enlarged uterine cavity. However, successful symptom relief has been shown in over two-thirds of cases even in those with a uterine size .12 weeks, although over a third of cases experienced at least one expulsion.…”

Section: Current Treatment Optionsmentioning

confidence: 99%

MR-guided focused ultrasound for the treatment of adenomyosis: current insights

Chin¹,

Walbridge²,

Quinn³

2015

RRFU

View full text Add to dashboard Cite

Adenomyosis is a benign gynecological condition causing significant morbidity among women of reproductive age. The available treatments are currently limited in number and efficacy. While hysterectomy is curative, it is unacceptable to many women, particularly those wishing to conserve their fertility. Magnetic resonance-guided focused ultrasound surgery is a noninvasive treatment method that has been used to effectively treat uterine leiomyomata, but until recently has not been routinely used to treat adenomyosis. This review summarizes the current understanding of adenomyosis and high-intensity focused ultrasound, and the recent research into the safety and efficacy of this technique.

show abstract

Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis

Cited by 48 publications

References 31 publications

Levonorgestrel-Releasing Intrauterine System in Adenomyosis; Predictors for Response and Clinical Outcome

Levonorgestrel-Releasing Intrauterine System in Adenomyosis; Predictors for Response and Clinical Outcome

Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding

MR-guided focused ultrasound for the treatment of adenomyosis: current insights

Contact Info

Product

Resources

About